Clinical Trial Update: Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 platform study of belantamab mafodotin as monotherapy and in combination for relapsed/refractory multiple myeloma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING